Laboratory indices in clofibrate therapy of juvenile‐onset diabetes

Narduzzi, J.V.; Danowski, T. S.; Weir, T. F.; Alley, R. A.; Vester, John W.; Moses, Campbell

doi:10.1002/cpt196786817

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only bezafibrate and clofibrate have been investigated in IDDM patients (92)(93)(94)(95) and found to be effective in reducing both VLDL and LDL levels. Only clofibrate and gemfibrozil are available in the U.S.…”

Section: Fibric Acid Derivativesmentioning

confidence: 99%

Management of Dyslipidemia in IPPM Patients

Garg

1994

Diabetes Care

View full text Add to dashboard Cite

Patients with insulin-dependent diabetes mellitus (IDDM) are at an increased risk for coronary heart disease. Factors that may enhance the risk include dyslipidemia, hypertension, and hyperglycemia. Until recently, the importance of dyslipidemia in IDDM was ignored because the prevalence of high cholesterol levels was similar to that in the nondiabetic population. However, unique abnormalities in the composition and metabolism of lipoproteins may occur in IDDM patients. Management of IDDM patients, therefore, should include control of dyslipidemia as well as control of hyperglycemia and hypertension. The therapeutic goals for serum cholesterol reduction in IDDM patients should be lower than that for nondiabetic patients, and the goals for children should be even lower than those for adults. Both very-low-density lipoprotein and low-density lipoprotein (LDL) levels should be the targets for therapeutic interventions and not just the LDL alone. Because of the unique features of dyslipidemia in IDDM patients, the therapeutic options may not be the same as that for nondiabetic patients. Hyperglycemia should be controlled by matching daily energy intake and activity with appropriately timed doses of insulin. The diets should be low in saturated fats and cholesterol. If dyslipidemia persists despite diet and hyperglycemia management, drug therapy may be initiated. For IDDM children > or = 10 years of age with elevated LDL-cholesterol levels, the first-line therapy should be bile acid sequestrants. For adults with IDDM, bile acid sequestrants also may be the drugs of choice, particularly for normotriglyceridemic patients. Nicotinic acid therapy should be avoided. Among other drugs, hydroxymethyl-glutaryl coenzyme A reductase inhibitors may be preferable for patients with elevated LDL cholesterol and borderline hypertriglyceridemia. Fibric acid derivatives should be used for markedly hypertriglyceridemic patients. The role of probucol for dyslipidemia in IDDM patients is not clear.

show abstract

Section: Fibric Acid Derivativesmentioning

confidence: 99%

Management of Dyslipidemia in IPPM Patients

Garg

1994

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…These intial observations were not confirmed by Danowski and co-workers who found improvement of glucose tolerance to be slight and confined to juvenile onset diabetics (Narduzzi et al, 1967;Vester et al, 1970). They studied a total of 48 maturity onset diabetics given clofibrate for 3 months to 4 years but failed to show significant improvement of glucose tolerance (Danowski et al, 1966;Vester et al, 1970).…”

Section: Discussionmentioning

confidence: 90%

“…Miller (1963) reported that oral glucose tolerance was significantly improved in eighteen diabetics given clofibrate for up to 11 months and in the same journal Herriot et al (1963) described four patients receiving chlorpropamide who showed improvement of intravenous glucose tolerance after clofibrate treatment for 3 months. These intial observations were not confirmed by Danowski and co-workers who found improvement of glucose tolerance to be slight and confined to juvenile onset diabetics (Narduzzi et al, 1967;Vester et al, 1970). They studied a total of 48 maturity onset diabetics given clofibrate for 3 months to 4 years but failed to show significant improvement of glucose tolerance (Danowski et al, 1966;Vester et al, 1970).…”

Section: Discussionmentioning

confidence: 90%

“…This and subsequent evidence (Berkowitz, 1971;Danowski, Cohn, Limaye, Novak, Saul, Sunder & Moses, 1965;Danowski, Novak, Saul, Vester & Moses, 1966; Narduzzi, Danowski, Weir, Alley, Vester & Moses, 1967;Vester, Sunder, Aarons & Danowski, 1970) has not led to general use of clofibrate as a specific treatment of diabetes because the effect has not been reliably reproduced. The study reported here was designed to ascertain the effect of clofibrate on oral glucose tolerance in maturity onset diabetics.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of clofibrate on glucose tolerance in maturity onset diabetes.

Barnett¹,

Craig²,

Robinson³

et al. 1977

Brit J Clinical Pharma

View full text Add to dashboard Cite

1 Fourteen maturity onset diabetics showed improvement of glucose tolerance while on treatment with clofibrate. Fasting blood glucose levels were reduced by 20% after treatment for 14 and 28 days. 2 The effect was found to be independent of concurrent treatment with oral hypoglycaemic drugs. 3 Plasma insulin levels were also lower during clofibrate treatment. 4 Clofibrate may prove to be a useful adjunct to the treatment of maturity onset diabetes.

show abstract

“…Data obtained in the first few months and the first year of therapy have been published previously. 4,7,27 The findings herein summarized are based on mean values recorded in the two groups prior to and at the end of 2 to 5 years of therapy. Measurements obtained several times each year were pooled and expressed as the mean value for that interval of time.…”

Section: Clinical Pharmacologymentioning

confidence: 99%